271. 強直性脊椎炎 Ankylosing spondylitis Clinical trials / Disease details

臨床試験数 : 563 / 薬物数 : 372 - (DrugBank : 72) / 標的遺伝子数 : 41 - 標的パスウェイ数 : 145

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR-TRC-13003449	2013-04-25	2013-06-07	A multicenter, randomized, double-blind, placebo-controlled, Phase II clinical study of Thalidomide in the treatment of Ankylosing Spondylitis	A multicenter, randomized, double-blind, placebo-controlled, Phase II clinical study of Thalidomide in the treatment of Ankylosing Spondylitis	Ankylosing Spondylitis	Thalidomide 150mg:Thalidomide 25mg/qd.po.2weeks; 50mg/qd.po.2weeks;100mg/qd.po.2weeks; 150mg/qd, po., to the end;Thalidomide 100mg:Thalidomide 25mg/qd.po.2weeks; 50mg/qd.po.2weeks; 100mg/qd.po.to the end;Control group:Placebo po.;	The General Hospital of People's Liberation Army	NULL	Completed	18	65	Both	Thalidomide 150mg:80;Thalidomide 100mg:80;Control group:40;	2 (Phase 2 study)	China
2	NCT02201043 (ClinicalTrials.gov)	February 2013	23/7/2014	Phase II Clinical Study of Thalidomide in the Treatment of Ankylosing Spondylitis	A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Clinical Study of Thalidomide in the Treatment of Ankylosing Spondylitis	Ankylosing Spondylitis	Drug: Thalidomide 150mg;Drug: Thalidomide 100mg;Drug: Placebo	Shanghai Pharmaceuticals Holding Co., Ltd	NULL	Completed	18 Years	65 Years	Both	197	Phase 2	China
3	ChiCTR-ONRC-10000858	2010-05-10	2010-04-28	Research on safety tolerance and pharmacokinetics of oral muti-dose Thalidomide	Research on safety tolerance and pharmacokinetics of oral muti-dose Thalidomide	Ankylosing Spondylitis	Group A:Muti-dose Thalidomide;GroupB:Muti-dose Thalidomide and Diclofenac sodium enteric-coated tablets ;	Chinese PLA General Hospital	NULL	Completed	18	45	Both	Group A:15;GroupB:12;	I (Phase 1 study)	China